术前NLR和PLR与肝门胆管癌根治术后临床病理特征及T分期的关系

李传涛; 周迟; 王兆映; 鲁正; 崔培元

doi:10.16766/j.cnki.issn.1674-4152.001993

术前NLR和PLR与肝门胆管癌根治术后临床病理特征及T分期的关系

doi: 10.16766/j.cnki.issn.1674-4152.001993

蚌埠医学院第一附属医院肝胆外科，安徽蚌埠 233004

基金项目:

安徽省自然科学基金 2008085MH256

详细信息

通讯作者:
崔培元, E-mail: Cpy666@126.com

中图分类号: R735.8
计量
- 文章访问数: 264
- HTML全文浏览量: 147
- PDF下载量: 2
- 被引次数: 0
出版历程
- 收稿日期: 2020-11-22
- 网络出版日期: 2022-02-16

Relationship between preoperative NLR and PLR and clinicopathological characteristics and T stage after laparoscopic radical resection of hilar cholangiocarcinoma

Department of Hepatobiliary Surgery, the First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui 233004, China

摘要

摘要: 目的收集近10年本科室肝门胆管癌(HC)患者的病例资料。研究术前中性粒细胞与淋巴细胞比(NLR)和血小板与淋巴细胞比(PLR)与HC临床病理特征及T分期的关系。方法回顾性分析2010年1月—2019年12月在蚌埠医学院第一附属医院肝胆外科术后病理为HC患者的资料，共有100例患者被纳入。通过受试者工作特征(ROC)曲线确定NLR和PLR的最佳截止值，统计分析术前NLR和PLR与HC病理特征及T分期的关系, 以及对T分期的预测价值。结果 ROC曲线确定最佳截止值，高NLR组(NLR>4.12, 56例)和低NLR组(NLR≤4.12, 44例)；高PLR组(>184.56, 48例)和低PLR组(≤184.56，52例)。单因素分析表明，术前NLR与肿瘤位置和T分期有相关性(均P < 0.05)，与性别、年龄、分化程度、肿瘤大小等无关(均P > 0.05)；术前PLR与T分期、肿瘤大小和淋巴结转移有相关性(均P < 0.05), 与性别、年龄、分化程度、肿瘤位置等无关(均P > 0.05)。多因素分析结果表明，术前NLR与T分期(OR=2.999, P=0.026)和肿瘤位置(OR=0.346, P=0.032)有关；术前PLR与T分期(OR=3.635, P=0.007)和肿瘤大小(OR=1.728, P=0.031)有关，与淋巴结转移转移无关(P > 0.05)。术前NLR和PLR的ROC曲线面积为0.811和0.794，对T分期有预测价值。结论术前NLR和PLR是一种简单、实用的检测指标，可用于术前对HC病理特征的评估，对T分期有预测价值。
- 肝门胆管癌 /
- 中性粒细胞与淋巴细胞比 /
- 血小板与淋巴细胞比
Abstract: Objective To study the relationship between preoperative neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) with the clinicopathological characteristics and T staging of hilar cholangiocarcinoma (HC). Methods The data of patients with HC were analyzed retrospectively. The receiver operating characteristic (ROC) curve was used to determine the best cut-off values of NLR and PLR. Statistical analysis of preoperative NLR and PLR and HC pathological characteristics and the relationship between T staging and the predictive value of T staging. Results The ROC curve was used to determine the best cut-off value: high-NLR group (NLR>4.12, 56 cases), low-NLR group (NLR≤4.12, 44 cases), high-PLR group (>184.56, 48 cases) and low-PLR group (≤184.56, 52 cases). Univariate analysis showed that preoperative NLR was correlated with tumour location and T stage (all P < 0.05) and had no correlation with gender, age, degree of differentiation and tumour size (all P > 0.05). Preoperative PLR was correlated with T stage, tumour size and lymph node metastasis (all P < 0.05) and had no correlation with gender, age, degree of differentiation and tumour location (all P > 0.05). Multivariate analysis showed that preoperative NLR was associated with T staging (OR=2.999, P=0.026) and tumour location (OR=0.346, P=0.032). Preoperative PLR was related to T stage (OR=3.635, P=0.007) and tumour size (OR=1.728, P=0.031), but not to lymph node metastasis (P > 0.05). The ROC curve areas of NLR and PLR before surgery were 0.811 and 0.794, respectively, which have predictive value for T staging. Conclusion Preoperative NLR and PLR are simple and practical detection indicators that can be used to evaluate the pathological characteristics of HC before surgery and have predictive value for T staging.
- Hilar cholangiocarcinoma /
- Neutrophil-to-lymphocyte ratio /
- Platelet-to-lymphocyte ratio

HTML全文

图 1 确定NLR和PLR最佳截止值的ROC曲线

下载: 全尺寸图片幻灯片

图 2 术前NLR和PLR与T分期的ROC曲线

下载: 全尺寸图片幻灯片

表 1 术前NLR水平与100例肝门胆管癌患者临床病理特征的关系(例)

项目	类别	例数	NLR		χ²值	P值
项目	类别	例数	高NLR组	低NLR组	χ²值	P值
性别	男性	67	39	28	0.402	0.526
	女性	33	17	16
年龄(岁)	>63	54	27	27	1.715	0.190
	≤63	46	29	17
分化程度	高	6	2	4
	中	73	42	31	1.332	0.906
	低	21	12	9
T分期	≥T2b	45	18	27	8.501	0.004
	<T2b	55	38	17
肿瘤大小(cm)	>2.5	45	30	15	3.778	0.052
	≤2.5	55	26	29
肿瘤位置	汇合部以上	52	35	17	5.622	0.018
	汇合部及以下	48	21	27
淋巴结转移	阳性	37	25	12	3.189	0.074
	阴性	63	31	32
TNM分期	>Ⅱ期	40	25	15	1.143	0.285
	≤Ⅱ期	60	31	29

下载: 导出CSV

表 2 术前PLR水平与100例肝门胆管癌患者临床病理特征的关系(例)

项目	类别	例数	PLR		χ²值	P值
项目	类别	例数	高PLR组	低PLR组	χ²值	P值
性别	男性	67	33	34	0.128	0.721
	女性	33	15	18
年龄(岁)	>63	54	22	32	2.478	0.115
	≤63	46	26	20
分化程度	高	6	1	5	4.046	0.132
	中	73	39	34
	低	21	8	13
T分期	≥T2b	45	14	31	9.350	0.002
	<T2b	55	34	21
肿瘤大小(cm)	>2.5	45	27	18	4.720	0.030
	≤2.5	55	21	34
肿瘤位置	汇合部以上	52	29	23	2.620	0.106
	汇合部及以下	48	19	29
淋巴结转移	阳性	37	24	13	6.692	0.010
	阴性	63	24	39
TNM分期	>Ⅱ期	40	24	16	2.620	0.106
	≤Ⅱ期	60	24	36

下载: 导出CSV

表 3 术前NLR与100例肝门胆管癌患者临床病理特征关系的多因素分析

影响因素	B	SE	Wald χ²	P值	OR(95%CI)
T分期	0.949	0.425	4.993	0.026	2.999(1.138~7.901)
肿瘤位置	0.894	0.425	4.420	0.032	0.346(0.131~0.911)

下载: 导出CSV

表 4 术前PLR与100例肝门胆管癌患者临床病理征特征关系的多因素分析

影响因素	B	SE	Wald χ²	P值	OR(95%CI)
T分期	-1.137	0.447	6.466	0.007	3.635(1.416~9.333)
肿瘤大小	1.105	0.448	6.074	0.031	1.728(1.050~2.846)
淋巴结转移	0.158	0.442	0.127	0.721	1.171(0.493~2.783)

下载: 导出CSV

参考文献(26)

[1]	RIZVI S, KHAN S A, HALLEMEEIER C L, et al. Cholangiocarcinomaevolving concepts and therapeutic strategies[J]. Nat Rev Clin Oncol, 2018, 15(2): 95-111. doi: 10.1038/nrclinonc.2017.157
[2]	ABDULLAH M, STUART R, JEREMY F, et al. Surgery for hilar cholangiocarcinoma: The newcastle upon tyne liver unit experience[J]. Eur Surg, 2019, 51(4): 197-205. doi: 10.1007/s10353-019-0599-4
[3]	JEROEN L, VAN V, MARCIA P, et al. The prognostic value of portal vein and hepatic artery involvement in patients with perihilar cholangiocarcinoma[J]. HPB, 2018, 20(1): 83-92. doi: 10.1016/j.hpb.2017.08.025
[4]	MICHAEL E, WILLIAM R. Surgical management of hilar cholangiocarcinoma at memorial sloan kettering cancer center[J]. Ann Gastroenterol Surg, 2018, 2(4): 304-312. doi: 10.1002/ags3.12181
[5]	SONG X, WANG Y, ZHANG A, et al. Advances in research on the interaction between inflammation and cancer[J]. J Int Med Res, 2019, 48(4): 300060519895347. http://www.ncbi.nlm.nih.gov/pubmed/31885347
[6]	ALLER M, ARIAS A, ARIAS J, et al. Carcinogenesis: The cancer cell-mast cell connection[J]. Inflamm Res, 2019, 68(2): 103-116. doi: 10.1007/s00011-018-1201-4
[7]	HUSZNO J, KOLOSZA Z, MROCHEM J, et al. The role of neutrophil-lymphocyte ratio, platelet-lymphocyte ratio, and platelets in the prognosis of metastatic renal cell carcinoma[J]. Oncology, 2019, 97(1): 1-11. doi: 10.1159/000499583
[8]	侯仕强, 金春景, 石碑田, 等. 术前NLR、PLR和MLR在胶质瘤患者预后中的应用研究[J]. 中华全科医学, 2020, 18(7): 1118-1121. https://www.cnki.com.cn/Article/CJFDTOTAL-SYQY202007016.htm
[9]	SAKAI M, SOHDA M, SAITO H, et al. Impact of combined assessment of systemic inflammation and presarcopenia on survival for surgically resected esophageal cancer[J]. Am J Surg, 2021, 221(1): 149-154. doi: 10.1016/j.amjsurg.2020.05.029
[10]	冯志强, 郭玉明, 赵君会, 等. 行肝切除术肝细胞癌患者炎性指标水平变化及与预后的相关性[J]. 中华实用诊断与治疗杂志, 2020, 34(9): 891-895. https://www.cnki.com.cn/Article/CJFDTOTAL-HNZD202009007.htm
[11]	ZHANG X, ZHAO W, YU Y, et al. Clinicopathological and prognostic significance of platelet-lymphocyte ratio (PLR) in gastric cancer: An updated meta-analysis[J]. World J Surg Oncol, 2020, 18(1): 191-203. doi: 10.1186/s12957-020-01952-2
[12]	孙家和, 刘元, 李志祥, 等. 术前中性粒细胞/淋巴细胞比值对cN0期甲状腺微小乳头状癌中央区淋巴结转移的预测价值[J]. 中华全科医学, 2020, 18(12): 2006-2009. https://www.cnki.com.cn/Article/CJFDTOTAL-SYQY202012009.htm
[13]	ZHU W, XIE W, ZHANG Z, et al. Postoperative complications and survival analysis of surgical resection for hilar cholangiocarcinoma: A retrospective study of fifty-nine consecutive patients[J]. Chin Med Sci J, 2020, 35(2): 157-169. http://www.sciencedirect.com/science/article/pii/S1001929420300353
[14]	CHUN Y, PAWLIK T, VAUTHEY J. 8th edition of the AJCC cancer staging manual: Pancreas and hepatobiliary cancers[J]. Ann Surg Oncol, 2018, 25(4): 845-847. doi: 10.1245/s10434-017-6025-x
[15]	DREYER S, POWELL A, MCSORLEY S, et al. The pretreatment systemic inflammatory response is an important determinant of poor pathologic response for patients undergoing neoadjuvant therapy for rectal cancer[J]. Ann Surg Oncol, 2017, 24(5): 1295-1303. doi: 10.1245/s10434-016-5684-3
[16]	PENG H, LUO X. Prognostic significance of elevated pretreatment systemic inflammatory markers for patients with prostate cancer: A meta-analysis[J]. Cancer Cell Int, 2019, 19(1): 70-88. doi: 10.1186/s12935-019-0785-2
[17]	RAKIC A, BEAUDRY P, MAHONEY D. The complex interplay between neutrophils and cancer[J]. Cell Tissue Res, 2018, 371(3): 517-529. doi: 10.1007/s00441-017-2777-7
[18]	VASUNDHARA S, MANU D, MANIKA V, et al. Systemic delivery of the tumor necrosis factor gene to tumors by a novel dual DNA-nanocomplex in a nanoparticle system[J]. Nanomedicine, 2017, 13(5): 1833-1839. doi: 10.1016/j.nano.2017.03.004
[19]	SONG W, PARTH T, DAVID A, et al. Conditioned medium from stimulated macrophages inhibits growth but induces an inflammatory phenotype in breast cancer cells[J]. Biomed Pharmacother, 2018, 106(10): 247-254. http://www.onacademic.com/detail/journal_1000040417512910_fa57.html
[20]	SUDAN S, DESHMUKH S, POOSARLA T, et al. Resistin: An inflammatory cytokine with multi-faceted roles in cancer[J]. BBA-Reviews on Cancer, 2020, 1874(2): 188419-188428. http://www.ncbi.nlm.nih.gov/pubmed/32822824
[21]	FENG Y, WANG J, TAN D, et al. Relationship between circulating inflammatory factors and glioma risk and prognosis: A meta-analysis[J]. Cancer Med, 2019, 8(17): 7454-7468. doi: 10.1002/cam4.2585
[22]	CHUAN T, WEI S, XIA T, et al. Prognostic significance of platelet-to-lymphocyte ratio in patients with ovarian cancer: A meta-analysis[J]. Eur J Clin Invest, 2018, 48(5): e12917. doi: 10.1111/eci.12917
[23]	GIAKOUSTIDIS A, NEOFYTOU K, C0STA N, et al. Identifying the role of neutrophil-to-lymphocyte ratio and platelets-to-lymphocyte ratio as prognostic markers in patients undergoing resection of pancreatic ductal adenocarcinoma[J]. J Hepatobiliary Pancreat Surg, 2018, 22(3): 197-207. doi: 10.14701/ahbps.2018.22.3.197
[24]	PORTIER I, CAMPBELL R. Role of platelets in detection and regulation of infection[J]. Arterioscler Thromb Vasc Biol, 2021, 41(1): 70-78. http://www.ncbi.nlm.nih.gov/pubmed/33115274
[25]	PLANTUREUX L, MEGE D, CRESCENCE L, et al. Impacts of cancer on platelet production, activation and education and mechanisms of cancer-associated thrombosis[J]. Cancers, 2018, 10(11): 441-464. doi: 10.3390/cancers10110441
[26]	HU H, JIN Y, ZHOU R, et al. Clinical value of inflammation-based prognostic scores to predict the resectability of hyperbilirubinemia patients with potentially resectable hilar cholangiocarcinoma[J]. J Gastrointest Surg, 2019, 23(3): 510-517. doi: 10.1007/s11605-018-3892-9